RecruitingNot ApplicableNCT07159789
Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
Non-Invasive Neuromodulation in MS Induced Spastic Paraparesis
Sponsor
Clinique Neuro-Outaouais
Enrollment
60 participants
Start Date
Oct 15, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria8
- Signed informed consent.
- Age ≥ 18 years and less than 71 years.
- Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
- EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
- Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.
- Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study.
- No change in disease modifying therapy for at least 3 months prior to screening.
- Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.
Exclusion Criteria6
- Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study.
- Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation.
- Pregnant or breastfeeding or intending to become pregnant during the study.
- Any previous rTMS therapy for any indication.
- Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker.
- Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.
Interventions
DEVICERepetitive Transcranial Magnetic Stimulation
Treatment with the rTMS or sham rTMS will be scheduled daily 5x per week for a total of 6 consecutive weeks followed, after a 6 week pause, by another treatment session of 6 weeks where all patients will receive active rTMS treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07159789
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT072253611 location